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A subset of circulating T cells (CD8
+CD45RO
 CD27
 ) with a naı ¨ve phenotype, but mediating effector function, is considered to
play an important role in host antitumour defence. To investigate the attributes of these effector T cells in patients with squamous cell
carcinoma (SCC) of the head and neck cancer, venous blood was obtained from 39 individuals with cancer and 45 normal controls
(NC). Peripheral blood mononuclear cells were isolated, stained with labelled monoclonal antibodies specific for CD8, CD45RO,
CD45RA, CD62L, CD27, TCR-z as well as isotype controls and examined by multicolour flow cytometry. Annexin V binding to
CD8
+ T cells and PMA/ionomycin-induced IFN-g expression were also evaluated in patients and NC. The proportions of
CD45RA
+CD45RO
  (naı ¨ve) and CD45RA
 CD45RO
+ (memory) cells were found to be comparable within the CD8
+ T-cell
subset. However, relative to NC, the frequency of effector CD8
+CD45RO
 CD27
  cells was strikingly increased in all SCC patients
regardless of the disease status (P¼0.0003). The proportion of these cells was found to increase with age in both patients and NC. In
NC, stimulated IFN-g expression was largely restricted to CD8
+CD45RO
 CD27
+ cells, while in patients CD8
+CD45RO
 CD27
 
expressed IFN-g after ex vivo stimulation. Expression of the TCR-associated z chain was decreased or absent in freshly isolated
CD8
+CD45RO
 CD27
  T cells in patients (Po0.0001). Annexin V was found to bind to a higher proportion of circulating CD8
+ T
cells in patients than NC (Po0.006), and significantly more Annexin V
+ T cells were present in the effector (Po0.0059) than the
naı ¨ve subset within the CD8
+CD45RO
  compartment. The data indicate that the expanded CD8
+CD45RO
 CD27
  T cells, which
contain precursors of IFN-g-producing T cells, are z-negative and sensitive to apoptosis in the circulation of patients with HNC.
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Recent data from our laboratory and other laboratories indicate
that tumour-infiltrating and peripheral T cells of many patients
with cancer are primed for apoptosis (Rabinowich et al, 1998;
Reichert et al, 1998b; Lee et al., 1999; Reichert et al, 2002;
Whiteside, 2002), and that the death of effector T cells could be
responsible for inadequate antitumour functions. We previously
reported that relative to healthy normal controls (NC), patients
with cancer have increased proportions of circulating T cells that
bind Annexin V (Dworacki et al, 2001; Hoffmann et al, 2002). This
observation suggests that a higher rate of lymphocyte turnover is
associated with cancer. Furthermore, we recently observed that
CD8
+ T cells are preferentially primed for apoptosis, suggesting a
more rapid turnover of CD3
+CD8
+ than CD3
+CD4
+ T cells
(Hoffmann et al, 2002). CD8
+ T cells are functionally hetero-
geneous, and several subsets of CD8
+ T cells are known to
contribute to antitumour immune responses. In addition to an
effector T cell subset, both naı ¨ve and memory CD8
+ T cells exist
within the peripheral CD8
+ T-cell pool (Hamann et al, 1997; Young
et al, 1997; Sallusto et al, 1999; Baares et al, 2000).
Human naı ¨ve and memory T cells can be identified by the
reciprocal expression of the CD45RA or CD45RO isoforms (Young
et al, 1997). More recent reports indicate that within the CD8
+
CD45RA
+(CD45RO
 ) compartment of naı ¨ve cells, a subset of
effector T cells, which lack the CD27 receptor as well as the lymph
node homing receptors CD62L and CCR7, can be identified
(Hamann et al, 1997; Sallusto et al, 1999). These effector-type
CD8
+CD45RO
 CD27
  T cells are thought to be derived from the
CD27
+ precursors in response to antigenic stimulation. They are
characterised by a shorter telomeric restriction fragment (TRF)
length compared with unprimed cells, express cytolytic activity
and abundantly produce IFN-g and TNF-a (Baares et al, 2000). It
has been suggested that this subset of CD8
+ T cells plays an
important role in host antitumour defence.
To further evaluate the role of this effector CD8
+ T-cell
subpopulation in the control of cancer progression, we investi-
gated the frequency and functional characteristics of effector CD8
+
T cells in a cohort of patients with squamous cell carcinoma (SCC)
of the head and neck. We find that, in contrast to normal controls,
the frequency of CD8
+CD45RO
 CD27
  T cells is significantly
increased in the circulation of HNC patients. However, these CD8
+
effector cells have no or low z expression and are thus unable to
signal. They also contain increased proportions of Annexin V-
binding cells. The data indicate that the CD8
+CD45RO
 CD27
 
effector T-cell subset appears to be dysfunctional and destined for
apoptosis in patients with cancer.
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Patients and controls
Venous blood samples (10–30ml) were obtained from patients
with SCC of the head and neck, who were seen between April 2001
and March 2002 at the Outpatient Otolaryngology Clinic at the
University of Pittsburgh Cancer Institute (UPCI). The Institutional
Review Board has approved the protocol for collection of patient
blood samples. Normal healthy donors (NC) were recruited among
the laboratory personnel and other volunteers. A written informed
consent was obtained from all individuals participating in this
study. Two groups of patients and NC were studied. In total, 28
patients and 38 NC were included in studies of CD8
+ T-cell subset
and analysis of CD3 z-chain expression. An additional 11 patients
and seven NC were included in the evaluation of Annexin V
binding to the CD8
+ effector T cells.
The characteristics of all the patients included in this study are
shown in Table 1. The cohort of 39 patients included 33 men and
six women with a mean age of 61 years (range 36–82). The group
of normal volunteers comprised 11 males and 34 females with a
mean age of 51 years (24–88). All patients had histologically
proven SCC of the head and neck, with 11 tumours originating in
the larynx, 12 in the oral cavity, 10 in the pharynx, two in the
hypopharynx and three at miscellaneous sites. One tumour was of
unknown origin. The histological grades of the tumours were well
differentiated (n¼2), moderately differentiated (n¼29), poorly
differentiated (n¼7) and undifferentiated (n¼1). At the time of
blood draw, 25 patients showed no evidence of disease, whereas 14
patients were studied either before surgery (n¼12) or had newly
diagnosed lymph node metastases (n¼2) and were classified as
having active disease.
Cell isolation
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll–Hypaque density gradient centrifugation, recovered from
the gradient interface, washed in Dulbecco’s phosphate-buffered
saline (D-PBS; Life Technologies, Inc., Grand Island, NY, USA),
counted in a trypan blue dye, and either stained for flow cytometry
or used for ex vivo experiments. In each experiment, PBMC
obtained from patients were evaluated together with the cells
obtained from at least one normal control.
Cell activation
PBMC obtained from patients or NC were suspended in AIMV
medium containing 10% (v/v) foetal bovine serum (FBS) (Life
Technologies, Rockville, MD, USA) at a concentration of
2 10
6cellsml
 1. Cells were stimulated with phorbol myristate
acetate (PMA, Sigma Chemical Co., St Louis, MO, USA) at 0.5ng
ml
 1 and 0.5mM ionomycin (Sigma) for 4, 12 or 18h followed by
4h incubation with 2mM monensin (Sigma). Cells were then
harvested for the determination of intracellular IFN-g expression
by flow cytometry. In other experiments, cells were stimulated with
anti-CD3mAb (10mgml
 1 Ortho Biotech, Bridgewater, NJ, USA),
and incubated for 24 or 48h in preparation for determinations of
z-chain expression as described below.
Staining for flow cytometry
Aliquots of PBMC were stained for flow cytometry, using a panel of
labelled monoclonal antibodies (mAbs) specific for cell surface-
associated lymphocyte antigens as follows: anti-CD8-PE-Cy5, anti-
CD45RO-ECD, anti-CD45RA-PE, anti-CD27-PE, anti-TCRz-PE,
anti-CD62L-FITC (all from Beckman Coulter, Miami, FL, USA)
and anti-CD27-FITC (Caltag Laboratories, Burlingame, CA, USA).
Isotype control Abs IgG1
  FITC or IgG1-PE were purchased from
Becton Dickinson (San Jose, CA, USA). FITC-conjugated Annexin
V was purchased from PharMingen (San Diego, CA, USA) and
anti-IFN-g-FITC mAbs from Beckman Coulter (Miami, FL, USA).
All antibodies were pretitred on normal PBMC to determine
optimal working concentrations. Freshly isolated PBMC were
incubated with antibodies for 25min on ice and washed twice in
PBS, containing 4% (v/v) FBS and 0.1% (vv
 1) NaN3. After
staining, the cells were fixed with 0.5% paraformaldehyde in PBS
prior to flow cytometry analysis. Staining for the TCR z chain or
IFN-g in CD8
+ T-cell subsets was performed as follows: first, the
cells were surface stained, then fixed with 0.5% paraformaldehyde
in PBS for 10min at room temperature and washed once with PBS/
FBS/NaN3 and once with 0.1% saponin (Sigma, St Louis, MO, USA)
in PBS containing 0.1% bovine serum albumin (BSA). The cells
were then stained either with anti-TCR-z-PE, IFN-g-PE or
respective isotype control Abs for 30min on ice in the dark. After
the incubation period, the cells were washed once in saponin
Table 1 Clinicopathological parameters of the patients with SCC of the
head and neck included in the study
n
Age (y)
Mean (range) 61 (36–82)
Sex
Male 33
Female 6
Total 39
Tumour site
Larynx
11
Oral cavity 12
Pharynx 10
Hypopharynx 2
Miscellaneous 3
Unknown 1
Tumour stage
T1
11
T2 14
T3 6
T4 5
TX 3
Nodal status
N0
21
N1 7
N2 11
Tumour differentiation
Well
2
Moderate 29
Poor 7
Undifferentiated 1
Prior therapy
a
Surgery
25
23
Radiotherapy 9
Chemotherapy 3
Smoking history
Yes
32
No 4
Unknown 3
Status at day of blood draw
No evidence of disease 25
Active disease (presurgery) 14
Primary 12
Recurrence 2
aTherapy ended X 2 months prior to the blood draw.
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British Journal of Cancer (2003) 88(2), 223–230 & 2003 Cancer Research UKsolution and once in PBS/FBS/NaN3 before fixation with 0.5%
paraformaldehyde in PBS.
To measure apoptosis, cells were surface stained and then
washed once with PBS/FBS/NaN3 and once with Annexin-binding
buffer (PharMingen), followed by incubation with FITC-conju-
gated Annexin V for 15min at room temperature. Flow cytometry
analysis was performed within 60min on a Coulter Epics XL flow
cytometer.
Statistical analysis
Linear regression analysis was conducted to assess the association
between the phenotypically defined T-cell subsets and age.
Estimated regression parameters were tested for homogeneity
between patients and controls. If changes in the subsets were
associated with age, differences between patients and controls were
adjusted to reflect the imbalance in age between the two groups. If
changes in subsets were independent of age, group differences
were examined using the Wilcoxon test for two group differences
(patients vs controls) or the Kruskal–Wallis test for three groups
(patients with active disease vs patients with no evident disease
(NED) vs controls). Differences with P-values of less than 0.05 were
considered to be significant.
RESULTS
Distribution of CD8
+ T-cell subsets in patients and NC
To study the heterogeneity of the peripheral CD8
+ T-cell pool, we
first evaluated the distribution of memory and naı ¨ve CD8
+ T cells
based on the surface expression of the CD45RA (‘naı ¨ve’) or
CD45RO (‘memory’) isoforms in patients and NC. There was no
significant difference in the proportion of CD45RA
+ naı ¨ve CD8
+ T
cells between patients and controls (Figure 1). In NC, the median
(range) for CD8
+CD45RA
+cells was 67% (24–80%) compared to
58% (24–83%) in patients. The CD8
+ CD45RO
+ memory cells
represented 37% (20–75%) of circulating CD8
+ cells in NC
compared to 43% (17–75%) in patients (Figure 1). Although
patients generally had fewer naı ¨ve CD8
+T cells and a higher
proportion of memory CD8
+ T cells than NC, these differences
were not statistically significant (P¼0.1641 and 0.1550, respec-
tively; Table 2).
We next examined the expression of CD27molecules on the
surface of peripheral blood CD8
+ T cells. The proportion of
CD8
+CD45RO
 CD27
  cells was found to be significantly greater in
patients than in NC (P¼0.0003; Table 2). The observed enrich-
ment of CD27-negative cells within the CD8
+CD45RO
  T-cell
compartment in patients with HNC was of special interest, because
the loss of CD27 expression has been reported to identify the
effector phenotype (Hamann et al, 1997). As illustrated in Figure 2,
CD27-negative T cells within the CD8
+CD45RO
  population were
expanded in the peripheral circulation of a patient, whereas
considerably fewer of these cells were present in the circulation of
an NC.
The cohorts of patients and NC were not age matched in our
study, and it was possible that the observed difference in the
proportion of CD8
+CD45RO
 CD27
  cells between these cohorts
was related to age. We therefore compared the patients and NC for
changes in this subset of cells relative to age. As Figure 3 shows,
the frequency of CD8
+CD45RO
 CD27
  T cells increased with age
in both patients and NC, but the percentage of these cells was
significantly higher in patients compared to healthy normal
individuals at all ages (P¼0.0003). We also examined the
proportion of the reciprocal subset of naı ¨ve CD8
+CD45RO
 CD27
+
T cells in the same patients as well as NC, and found that it
decreased with age and was significantly lower in patients than in
controls (data not shown).
In addition to lacking CD27, the effector CD8
+ T-cell
subset was also reported to lack the lymph node homing
receptor CD62L (Sallusto et al, 1999). In our cohort of NC, the
expression of CD62L within the CD8
+CD45RO
 CD27
  population
was found to be very low with a mean7s.d. of 4%74 (Table 2). In
agreement with the data reported in the literature, the CD27-
negative effector CD8
+ T cells were also CD62L-negative, and the
proportion of these cells was highly elevated in the peripheral
circulation of patients (50%723) relative to NC, (25%723).
Representative data for one patient and an age-matched control
are shown in Figure 4.
Within the memory CD8
+CD45RO
+ lymphocyte subset, the
proportions of CD27-negative and CD27
+ cells were found to be
comparable in patients and NC (P¼0.38 and 0.39, respectively).
The subset of CD8
+CD45RO
+CD27
+ cells decreased with age in
both patients and NC, while the reciprocal subset of
CD8
+CD45RO
+CD27
  cells showed an increase with age in both
groups (data not shown).
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Figure 1 Box and whisker plots showing the percentages of CD45RA
+ (naı ¨ve) and CD45RO
+ (memory) cells among CD8
+ T cells in normal controls
and patients. The white bar is the median, the black box is the interquartile range (25–75%) and the whiskers extend to 1.5 times the interquartile range.
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British Journal of Cancer (2003) 88(2), 223–230 & 2003 Cancer Research UKThe percentage of effector CD8
+CD45RO
 CD27
  T cells was not
found to be significantly different among patients with active
disease or those who had no evidence of disease (NED). Likewise,
patients with tumours at different sites or with tumours at distinct
stages of differentiation had similar percentages of effector CD8
+ T
cells (data not shown).
Stimulated IFN-c expression in CD8
+ T-cell subsets
PBMC of patients and controls were cultured in the presence of
PMA/ionomycin, stained for IFN-g expression and examined by
flow cytometry to determine the distribution of precursors of IFN-
g-producing cells among CD8
+ T-cell subsets. Stimulated IFN-g
expression was found to be largely confined to CD27
+ T cells in
NC. However, in cancer patients, most of IFN-g
+ cells were CD27-
negative following stimulation with PMA and ionomycin (Figure 5).
While the proportions of IFN-g
+CD27
  T cells observed after ex
vivo stimulation varied broadly in different patients, the pre-
cursors of IFN-g-producing cells were consistently found within
the CD8
+CD45RO
 CD27
  compartment in patients and within the
CD8
+CD45RO
 CD27
+ subset in NC. Freshly isolated, noncultured
subsets of CD8
+CD45RO
  cells expressed no IFN-g in patients or
NC. Thus, the CD27-negative subset, which is expanded in
patients, contains precursors of IFN-g-producing effector CD8
+ T
cells.
Expression of TCR f in CD8
+ T-cell subsets
In order to verify the functional integrity of the TcR signalling
pathway in CD8
+ effector T cells in the peripheral circulation, we
next determined the expression of TCR-associated z chain in
CD8
+CD45RO
 CD27
  effector T cells in an additional 13 patients
with SCC of the head and neck and 16 NC. We observed a
significantly decreased mean fluorescence intensity (MFI) for z in
patients relative to NC (Figures 6 and 7), with an MFI of 194 (range
15–782) compared to 760 (range 19–1385) in NC (Po0.0001).
Thus, although this subset of effector cells was expanded in
patients relative to NC, the near absence of z expression in effector
T cells suggested that their signalling via TcR was compromised.
Expression of the z chain was also found to be depressed in the
naı ¨ve and memory subsets of CD8
+ T cells in these patients (data
not shown). When PBMC of patients and controls were stimulated
with anti-CD3mAb, expression of z in CD8
+ T cells was lower in
patients than in NC at 24 and 48h of culture (data not shown).
Annexin V binding to CD8
+ effector T cells
We have previously reported that decreased z-chain expression
could be related to programmed cell death of circulating CD3
+ T
cells in patients with cancer (Gastman et al, 1999; Dworacki et al,
2001; Hoffmann et al, 2002). To investigate whether apoptosis
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Figure 2 Representative flow cytometry data, illustrating an increase in the proportion of CD27-negative cells among CD8
+CD45RO
  T cells in the
patient. The percentages of positive cells in each quadrant are shown in the right upper corner.
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Figure 3 Correlations between age (in years) and the percentages of
CD27-negative cells among CD8
+CD45RO
  lymphocytes in the periph-
eral blood of patients and normal controls. The P-value for the significance
of differences in the percentage of these lymphocytes between patients
and controls has been calculated after adjustment for the age difference
between these groups.
Table 2 Proportions and mean fluorescence intensity of z in CD8
+ T-
cell subsets in patients with SCC of the head and neck and normal controls
Patients Controls
% Positive cells n Mean s.d. n Mean s.d. P-value
CD8
+CD45RA
+(RO
 )2 7 5 7 717 35 63 715 0.1641
CD8
+CD45RO
+(RA
 )2 7 4 3 717 35 38 715 0.1550
CD27
  in CD8
+CD45RO
  28 48 719 38 37 719 0.0003
a
CD27
 CD62L
  in CD8
+
CD45RO
 
28 50 723 38 25 723 0.0001
a
CD27
 CD62L
+ in CD8
+
CD45RO
 
28 4 773 8 4 74 0.508
a
z in CD8
+CD45RO
 CD27
 b 13 194 7256 16 759 7346 o0.0001
aAge-dependent subsets, adjusted means and P-values.
bMean fluorescence intensity.
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British Journal of Cancer (2003) 88(2), 223–230 & 2003 Cancer Research UKcould account for the observed decreased z expression in
CD8
+CD45RO
 CD27
  effector T cells, we studied Annexin V binding
to subpopulations of naı ¨ve, effector and memory CD8
+ T cells in a
subset of our patients. In agreement with our previously reported
data (Hoffmann et al, 2002), we observed that a greater proportion of
CD8
+ T cells bound Annexin V in patients than in NC (P¼0.006).
Furthermore, when Annexin V binding to the cells within the
CD8
+CD45RO
  compartment was evaluated in patients, significantly
more CD27-negative-Annexin-binding T cells were observed relative
to NC (P¼0.0059), as shown in Figure 8. Thus, while this subset of
effector cells was expanded in patients with cancer, a higher
proportion of the cells were in early apoptosis in patients than in
NC. There was almost no binding of Annexin detected among the
remaining naı ¨ve subset of CD8
+ T cells, while in the memory
compartment (CD8
+CD45RO
+), the proportion of Annexin-binding
cells was increased in patients relative to NC (Figure 8).
DISCUSSION
Our earlier observations indicated that CD8
+ lymphocytes are
preferentially targeted for apoptosis in patients with advanced
cancer (Hoffmann et al, 2002). This finding has focused our
attention on the subsets of CD8
+ T cells and their susceptibility
to apoptosis. Among the subsets of CD8
+ T cells,
CD8
+CD45RO
 CD27
  cells are considered to be responsible for
effector functions (Hamann et al, 1997; Sallusto et al, 1999; Baares
et al, 2000). The phenotypic and functional characteristics of these
cells have been extensively investigated and are consistent with
their status of antigen-primed effector cells (Baares et al, 2000;
Hendrics et al, 2000). In tumour-bearing hosts, these cells are
likely to play an important role in the control of tumour growth.
Thus, we were especially interested in the fate of
CD8
+CD45RO
 CD27
  in patients with cancer.
By multicolour flow cytometry, it was possible to differentiate
between the naı ¨ve, memory and effector subsets of CD8
+ T
lymphocytes, using antibodies to well-recognised surface markers
CD45RA and CD45RO in combination with CD27 or CD62L
(Hamann et al, 1997; Young et al, 1997). Strikingly, we observed
that the population of CD8
+CD45RA
+CD27
  T cells was greatly
expanded in the circulation of patients with SCC of the head and
neck. This finding was readily explainable by the accelerated
recruitment of naı ¨ve T cells into the effector and memory cell
pools. Indeed, the overall proportion of naı ¨ve CD8
+CD45RA
+ T
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and a patient with cancer after 18h of in vitro stimulation with PMA and ionomycin as described in Materials and Methods. Note that effector T cells
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British Journal of Cancer (2003) 88(2), 223–230 & 2003 Cancer Research UKcells (including effector cells) was somewhat lower and that of
memory CD8
+CD45RO
+ cells higher in patients than in controls
(Figure 1) although these differences did not reach statistical
significance. The expansion of the effector cell pool in patients was
not found to be an age-dependent process (Figure 3), as it was
present in young and old patients. It was viewed by us as a
potentially important manifestation of host antitumour defence.
Furthermore, ex vivo stimulation of patients’ PBMC with PMA/
ionomycin showed that the expanded CD8
+CD45RO
 CD27
 
subset contained precursors of IFN-g-producing cells, confirming
the effector cell status of this population (Hamann et al, 1997;
Young et al, 1997). However, we discovered that practically all of
the T cells in the effector subset had low or no z expression. This
finding indicated that signalling via TcR was dysfunctional in
expanded CD8
+CD45RO
 CD27
  cells of patients with cancer. Our
results suggest that this subset of effector cells is dysfunctional in
cancer patients. While patients’ T cells may recover expression of z
in part during ex vivo stimulation with anti-CD3mAb, z remained
low at 24 or 48h of culture relative to its expression in normal T
cells incubated in parallel.
Downregulation of z expression has been reported in T and
NK cells of patients with cancers (Zea et al., 1995; Rabinowich et al,
1996, 1998; Reichert et al, 1998a,b; Kiessling et al, 1999; Kuss et al,
1999; Whiteside, 1999, 2002; Meidenbauer et al, 2002; Reichert et al,
2002) and with chronic infections, including HIV (Stefanova et al,
1996; Zea et al., 1998). A transient loss of z expression appears to
be a normal consequence of signalling via TcR (Valiutti et al,
1997). However, in patients with cancer or chronic infections such
as leprosy or HIV, z expression may never recover to equal that in
normal T cells (Stefanova et al, 1996; Zea et al., 1998), and its
absence or partial loss in cancer patients appears to be
substantially more common in tumour-infiltrating than in
circulating T lymphocytes (Otsuji et al, 1996). Several different
mechanisms have been proposed to explain the loss of z
expression, including production of reactive oxygen metabolites
(ROM) by tumour or tumour-associated monocytes (Kono et al,
1996; Otsuji et al, 1996), or by circulating activated granulocytes
(Schmielau and Finn, 2001); apoptosis in the tumour microenvir-
onment (Gastman et al, 1999; Hoffmann et al, 2002; Whiteside,
2002); production and release by the tumour of z inhibitory
proteins (Taylor et al, 2001); the availability of L-arginine in the
microenvironment (Taheri et al, 2001) or increased degradation of
z in chronically activated T cells (Penna et al, 1999). It is
interesting to note that the loss of z was observed not only in the
CD8
+CD45RA
+CD27
  subset of effector cells, but also in other
CD8
+ T-cell subsets of patients with SCC of the head and neck.
Therefore, in agreement with our previously reported data, z
downregulation appears to be a generalised phenomenon in cancer
patients, which might be mediated by several distinct mechanisms
(Kiessling et al, 1999; Whiteside, 1999; Dworacki et al, 2001).
It is possible that the observed low or absent z expression in
CD8
+ T cells of patients with cancer is a consequence of normal
antigen engagement in this effector cell population, consistent with
their antitumour activity. The cells were able to recover respon-
siveness after ex vivo stimulation with PMA/ionomycin, as
evidenced by IFN-g expression. However, not all cells responded
by IFN-g expression, and in some patients we studied, none
responded. It appears that the expanded precursors of IFN-g
producing effector cells in patients with SCC of the head and neck
are functionally crippled, and that the mechanism responsible for
their dysfunction may be low or absent z expression. In this
respect, it is interesting to note that z is slowly emerging as a
biomarker of survival and prognosis as well as responsiveness to
immune therapy in patients with cancer (Zea et al., 1995; Reichert
et al, 1998a,b; Meidenbauer et al, 2002).
The finding of increased Annexin binding to the
CD8
+CD45RO
 CD27
  cell subset in patients relative to NC
indicated that low z expression might be related to apoptosis, as
previously suggested (Gastman et al, 1999; Dworacki et al, 2001;
Hoffmann et al, 2002). As indicated above, the subset of
CD8
+CD45RA
+CD27
  effector cells was not the only subset with
a higher rate of apoptosis and low z expression in CD8
+ T cells of
patients with cancer. In these patients, the memory CD8
+
compartment was similarly affected. Only the naı ¨ve
CD8
+CD45RO
 CD27
+ subset of T cells showed a relatively low
rate of apoptosis, which was comparable to that of normal naı ¨ve
cells. Although the CD8
+CD45RA
+CD27
  effector cell subset was
not selectively targeted for apoptosis, z downregulation, greater
sensitivity to apoptosis and the concomitant decreased functional
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Figure 6 Representative flow cytometry histogram, showing MFI of the z
chain in effector T cells of a patient and an NC. The gate was set on
CD8
+CD45RO
 CD27
  effector T cells. Note the substantial decrease of
z MFI in the patient’s T cells.
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Figure 7 Box and whisker plots showing MFI for TCR-associated z chain
in effector T cells of patients and NC. The gate was set on CD8
+
CD45RO
 CD27
  effector T cells. See the legend to Figure 1 for an
explanation of the box plot.
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antitumour activity, is likely to have a negative impact on the host
response to the tumour.
The seemingly contradictory observations of the expanded
effector cell pool and increased apoptosis as well as z degradation
within this CD8
+ subset could be reconciled by considering
lymphocyte turnover in a tumour-bearing host. Under conditions
of chronic antigenic stimulation, lymphocyte turnover is likely to
be increased owing to an increased rate of antigen-driven
expansion and activation-induced cell death (AICD), as previously
suggested (Van Parijs and Abbas, 1998). Hence, the expansion of
the effector cell subset in patients with cancer could be viewed as a
natural consequence of response to tumour-associated antigens.
The concomitant loss of function and death of activated T
lymphocytes are compensated for by the sequestration and release
of new T cells from the bone marrow stores (Tough and Sprent,
1994; Mackall et al, 1997). However, the pool of naı ¨ve CD8
+ T cells
is not increased because of their rapid maturation and transfer to
the antigen-experienced compartment. This series of events is
consistent with a high rate of lymphocyte turnover in patients with
cancer, not unlike that seen in patients with HIV (Mohri et al,
1998; Hellerstein et al, 1999). The obvious downside of such rapid
turnover in T cells is that the normal processes of maturation and
differentiation of effector cells are disturbed, possibly leading to
ineffective immune responses. Further studies will be necessary to
confirm directly the hypothesis linking signalling defects we
observed with apoptosis and rapid lymphocyte turnover in
patients with cancer.
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